Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Estimating Metastatic Disease Heterogeneity Using Radiomics-based Lesion Clustering and Heterogeneity Index - Application in Lung Adenocarcinoma Patients and Correlations With Patient Outcomes.

Journal of imaging informatics in medicine·2026
Same author

GABA promotes resistance to immunotherapy in patients with TLS-positive tumors.

Cancer cell·2026
Same author

A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.

Molecular cancer·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Feb 27, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Olaratumab for soft tissue sarcoma.

Diego Teyssonneau1, Antoine Italiano1

  • 1a Early Phase Trials and Sarcoma Units , Institut Bergonié , Bordeaux , France.

Expert Opinion on Biological Therapy
|July 11, 2017
PubMed
Summary

Olaratumab, an anti-PDGFR-α antibody, significantly improved overall survival for patients with soft tissue sarcomas (STS) when added to doxorubicin treatment. Further Phase 3 trials are ongoing to confirm these promising results for advanced STS.

Keywords:
Olaratumabplatelet-derived growth factor receptor alphasoft tissue sarcoma

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Related Experiment Videos

Last Updated: Feb 27, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.9K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Soft tissue sarcomas (STS) are rare cancers with limited treatment advancements since the 1970s.
  • Platelet-derived growth factor receptor alpha (PDGFR-α) is implicated in sarcoma growth and angiogenesis.
  • Olaratumab is a novel monoclonal antibody targeting PDGFR-α.

Purpose of the Study:

  • To evaluate the efficacy and safety of olaratumab in combination with doxorubicin for unresectable or metastatic STS.
  • To assess the impact of olaratumab on overall survival (OS) in STS patients.

Main Methods:

  • A randomized Phase II JDGD trial was conducted.
  • Patients received doxorubicin with or without olaratumab.
  • Overall survival (OS) and toxicity were primary endpoints.

Main Results:

  • The addition of olaratumab to doxorubicin increased median OS from 14.7 to 26.5 months.
  • The combination therapy demonstrated acceptable toxicity profiles.
  • Results suggest a significant survival benefit for STS patients treated with olaratumab.

Conclusions:

  • Olaratumab shows promise as a new therapeutic option for STS, significantly improving survival outcomes.
  • Further investigation in a Phase 3 trial (JGDJ) is warranted to validate these findings and address study uncertainties.